Amneal Pharmaceuticals, Inc. (AMRX)

NasdaqGS Currently up 0.22 (+1.24%) in today's trading session

2 members of Congress have disclosed 3 trades in Amneal Pharmaceuticals, Inc. (AMRX) via STOCK Act filings. The most recent disclosure was a sale by Gilbert Cisneros on 29 May 2019. The most active traders have been Josh Gottheimer (2) and Gilbert Cisneros (1). Aggregate disclosed activity totals roughly $24K in sales (midpoint estimates from bracketed disclosure amounts).

Amneal Pharmaceuticals, Inc. is currently trading at $17.97, positioned at 96% of its 52-week range ($7.67 – $18.39).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$17.97
24h Change
+0.22 (+1.24%)
52 Week Range
$7.67$18.39
View on NASDAQ

Amneal Pharmaceuticals, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for AMRX

Select to highlight on chart
2 transactions
Compliance: 67%
Gilbert Cisneros29 May 201918 Jun 2019SaleStock$1,001 - $15,000N/A
Josh Gottheimer24 May 201915 Jun 2019SaleStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$5.74B

Volume

2.28M

Beta

1.26

P/E Ratio

19.97

Fundamentals

EPS

$0.90

Div. Yield

Open

$17.56

Day Range

$17.50 — $18.04

Company Information

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ · USD
Country
US
CEO
Chirag K. Patel
IPO Date
2018-05-07

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medic...

Earnings

Next Report

Q2 2026

30 Jul

EPS Est.

$0.24

Rev. Est.

$768.2M

Days Until

7

Recent Quarters

Q1 20267 May
EPS$0.27
Beat 58.8%
Q4 202527 Feb
EPS$0.21
Beat 16.7%
Q3 202530 Oct
EPS$0.17
Beat 30.8%
Q2 20255 Aug
EPS$0.25
Beat 38.9%
Q1 20252 May
EPS$0.21
Beat 40.0%
Q4 202428 Feb
EPS$0.12
Miss 20.0%
Q3 20248 Nov
EPS$0.16
Beat 23.1%
Q2 20249 Aug
EPS$0.16
Beat 14.3%
Q1 20243 May
EPS$0.14
Beat 55.6%
Q4 20231 Mar
EPS$0.14
Beat 100.0%
Q3 20237 Nov
EPS$0.19
Beat 58.3%
Q2 20234 Aug
EPS$0.19
Beat 90.0%
Q1 20235 May
EPS$0.12
Beat 33.3%
Q4 20222 Mar
EPS$0.23
Beat 9.5%
Q3 20224 Nov
EPS$0.14
Miss 22.2%
Q2 20225 Aug
EPS$0.19
Miss 5.0%
Q1 20224 May
EPS$0.12
Beat 0.0%
Q4 20212 Mar
EPS$0.18
Miss 5.3%
Q3 20213 Nov
EPS$0.21
Beat 5.0%
Q2 20219 Aug
EPS$0.25
Beat 38.9%
Q1 20217 May
EPS$0.20
Beat 11.1%
Q4 202026 Feb
EPS$0.14
Beat 7.7%
Q3 20206 Nov
EPS$0.16
Beat 23.1%
Q2 20206 Aug
EPS$0.13
Beat 30.0%
Q1 202011 May
EPS$0.20
Beat 150.0%
Q4 201926 Feb
EPS$0.08
Beat 60.0%
Q3 20196 Nov
EPS$0.04
Miss 69.2%
Q2 20195 Aug
EPS$0.09
Miss 40.0%
Q1 20199 May
EPS$0.14
Miss 22.2%
Q4 201828 Feb
EPS$0.33
Beat 26.9%
Q3 20187 Nov
EPS$0.28
Beat 3.7%
Q2 20189 Aug
EPS$0.24
Beat 4.3%
Q1 20187 May
EPS$0.14
Miss 17.6%
Q4 20171 Mar
EPS$0.11
Beat 0.0%
Q3 20179 Nov
EPS$0.23
Beat 15.0%
Q2 20179 Aug
EPS$0.18
Beat 28.6%
Q1 201710 May
EPS$0.11
Miss 15.4%
Q4 20161 Mar
EPS$0.16
Beat 0.0%
Q3 20169 Nov
EPS$0.37
Miss 2.6%
Q2 20169 Aug
EPS$0.21
Miss 34.4%
Q1 201610 May
EPS$0.43
Beat 10.3%
Q4 201522 Feb
EPS$0.62
Beat 40.9%
Q3 20159 Nov
EPS$0.40
Beat 2.6%
Q2 201510 Aug
EPS$0.34
Miss 2.9%
Q1 201511 May
EPS$0.09
Miss 50.0%
Q4 201424 Feb
EPS$0.16
Beat 33.3%
Q3 20144 Nov
EPS$0.33
Beat 6.5%
Q2 20146 Aug
EPS$0.60
Beat 66.7%
Q1 20141 May
EPS$0.24
Beat 380.0%
Q4 201320 Feb
EPS$-0.02
Miss 160.1%
Q3 20134 Nov
EPS$0.25
Beat 457.1%
Q2 20138 Aug
EPS$0.23
Beat 452.0%
Q1 20131 May
EPS$0.37
Beat 85.0%
Q4 201225 Feb
EPS$0.30
Beat 57.9%
Q3 201230 Oct
EPS$0.48
Miss 4.0%
Q2 201231 Jul
EPS$0.60
Beat 33.3%
Q1 20121 May
EPS$0.55
Beat 12.2%
Q4 201128 Feb
EPS$0.36
Beat 63.6%
Q3 20111 Nov
EPS$0.30
Beat 30.4%
Q2 20112 Aug
EPS$0.22
Beat 15.8%
Q1 20113 May
EPS$0.24
Beat 60.0%
Q4 201024 Feb
EPS$0.23
Beat 4.5%
Q3 20102 Nov
EPS$0.24
Miss 7.7%
Q2 20103 Aug
EPS$0.48
Miss 5.9%
Q1 20104 May
EPS$2.06
Beat 303.9%
Q4 200925 Feb
EPS$0.69
Beat 392.9%
Q3 20093 Nov
EPS$0.11
Beat 120.0%
Q2 20094 Aug
EPS$0.05
Beat 66.7%
Q3 20049 Nov
EPS$0.01
Miss 80.0%
Q2 20044 Aug
EPS$0.01
Miss 61.5%
Q1 20045 May
EPS$0.14
Beat 566.7%
Q4 200317 Feb
EPS$-0.05
Beat 0.0%
Q3 20035 Nov
EPS$-0.07
Miss 180.0%
Q2 200328 Jul
EPS$-0.05
Beat 16.7%
Q1 200330 Apr
EPS$-0.07
Beat 12.5%
Q4 200212 Feb
EPS$-0.07
Beat 36.4%
Q3 200228 Oct
EPS$-0.11
Beat 15.4%
Q2 200225 Jul
EPS$-0.13
Miss 8.3%
Q1 200230 Apr
EPS$-0.12
Beat 7.7%
Q4 20017 Feb
EPS$-0.15
Miss 7.1%
Q3 200130 Oct
EPS$-0.15
Miss 7.1%
Q2 200131 Jul
EPS$-0.15
Beat 16.7%
Q1 20012 May
EPS$-0.16
Beat 23.8%
Q4 20008 Feb
EPS$-0.20
Beat 13.0%
Q3 200031 Oct
EPS$-0.18
Beat 14.3%
Q2 200031 Jul
EPS$-0.21
Miss 16.7%

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about AMRX

Which members of Congress have traded AMRX?
2 members of Congress have disclosed 3 trades in Amneal Pharmaceuticals, Inc. (AMRX) under the STOCK Act. The most active traders are Josh Gottheimer and Gilbert Cisneros.
When was AMRX most recently disclosed by Congress?
The most recent AMRX disclosure was a sale by Gilbert Cisneros on 29 May 2019.
What is the total disclosed congressional trading volume for AMRX?
Members of Congress have disclosed approximately $24K in AMRX sales (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in AMRX?
This AMRX page updates as soon as new STOCK Act disclosures are filed for Amneal Pharmaceuticals, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.